Fundraising FoxBraidwell — 2026 Investments
4 investments dated 2026 · listed companies and verified rows first · show all
Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.
BiotechHealthtechNew York, US
Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)inEliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)
Co-investorsBioAdvanceBAM ElevateCommodore CapitalJanus Henderson InvestorsOrbiMedRA Capital+2 more
Encoded develops gene therapies for neurological disorders through an integrated platform approach.
BiotechSouth San Francisco, US
Stephanie Tagliatela(Founder)inKartik Ramamoorthi, Ph.D.(Co-founder, Chief Executive Officer & Board Member)Kartik Ramamoorthi(Founder)
Co-investorsARCH Venture PartnersBioBritGV (Google Ventures)Illumina VenturesMenlo VenturesQuonota Investments+7 more
Prompt is an Ambient AI product and research company that develops human-centered AI products designed to sense the physical environment.
AI & Machine LearningConsumerDeep TechSan Francisco, US
Tete Xiao(Founder)in
Co-investorsAbstract VenturesAIX VenturesDCVC (Data Collective)Laude VenturesNeotribe VenturesAlexandria+4 more
Proxima develops AI-powered gaming experiences and infrastructure, with a focus on embodied AI agents and applied AI systems for interactive entertainment.
AI & Machine LearningGamingSan Francisco, US
Ran Mo(Founder)in
Co-investorsAIX VenturesKonvoy VenturesProgressionAlexandriaBalderton CapitalBayern Kapital+9 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.